Moviprep

Ascorbic Acid, the active ingredient in Moviprep, is a bowel preparation presented as an oral solution for oral use. It, together with sodium ascorbate, potassium chloride, sodium chloride and sodium sulfate, creates an osmotic effect that cleanses the colon before diagnostic procedures such as colonoscopy or sigmoidoscopy. The formulation is approved in the European Union and is indicated for bowel cleansing prior to endoscopic examinations.

GNH USA supplies Moviprep as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

Moviprep is an oral bowel preparation that facilitates colonic cleansing before endoscopic procedures.

- Colonoscopy: provides thorough bowel cleansing to improve visualization of the colon during the procedure. - Sigmoidoscopy: clears the distal colon and rectum, allowing accurate assessment during the examination. - Pre‑colorectal surgery: ensures a clean intestinal tract to reduce infection risk and improve surgical conditions.

Moviprep may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild to moderate feeling of sickness. - Abdominal discomfort: cramping or pain in the stomach area. - Bloating: sensation of fullness due to gas. - Vomiting: occasional expulsion of stomach contents. - Thirst: increased desire to drink fluids. - Mild electrolyte imbalance: temporary changes in sodium or potassium levels.

Serious or Rare Side Effects: - Severe dehydration: marked loss of body fluids requiring medical attention. - Significant electrolyte disturbances: such as hypokalemia or hyponatremia. - Renal impairment: reduced kidney function in susceptible individuals. - Severe abdominal pain: persistent or worsening pain. - Allergic reaction: rash, itching, or swelling. - Colonic perforation: extremely rare but life‑threatening injury to the bowel wall.

Before prescribing Moviprep, clinicians should consider several safety precautions to minimize risk.

- Renal function assessment: evaluate kidney health to avoid worsening impairment. - Electrolyte monitoring: check baseline sodium and potassium levels, especially in at‑risk patients. - Dehydration status: ensure patients are adequately hydrated before starting the regimen. - Gastrointestinal disease: use with caution in active inflammatory bowel disease or recent bowel surgery. - Concomitant laxatives: avoid combining with other strong laxatives to prevent excessive fluid loss. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Moviprep can interact with other medicines, affecting electrolyte balance or renal function.

Major Interactions (Avoid): - Other osmotic laxatives: increase risk of severe dehydration and electrolyte loss. - Loop diuretics: may exacerbate hypovolemia and electrolyte disturbances. - ACE inhibitors or ARBs: heightened risk of renal dysfunction when combined. - NSAIDs: can further impair kidney function in susceptible patients. - Potassium‑sparing diuretics: may lead to abnormal potassium levels.

Moderate Interactions (Monitor Closely): - Antacids: may alter gastrointestinal pH, affecting tolerability. - Oral electrolyte solutions: adjust dosing to prevent over‑correction of electrolytes. - Certain antibiotics (e.g., fluoroquinolones): monitor for gastrointestinal side‑effects.